Actively Recruiting
IOP Elevation Study
Led by NYU Langone Health · Updated on 2023-08-31
150
Participants Needed
1
Research Sites
322 weeks
Total Duration
On this page
Sponsors
N
NYU Langone Health
Lead Sponsor
N
National Eye Institute (NEI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to improve understanding of the pathophysiologic process that leads to the development of glaucamotous damage. The mechanism by which vision loss in glaucoma occurs is still unknown, but it is clear that increased intraocular pressure (IOP) is a major risk factor. It is also thought that the LC is a site of primary damage during pathogenesis of the disease. This prospective study with determine the in-vivo mechanical response to IOP modulation at the level of the ONH and LC.
CONDITIONS
Official Title
IOP Elevation Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy volunteers with no family history of glaucoma (first-degree relative)
- No history of intraocular pressure greater than 22 mmHg
- Normal appearing optic discs and retinal nerve fiber layer on dilated eye exam
- Normal visual field test results defined by glaucoma hemifield test within normal limits
- Glaucoma suspects with normal visual fields and either intraocular pressure between 25 to 30 mmHg with central corneal thickness less than 550 microns or a difference of 0.2 or more in cup to disc ratio between eyes
- Individuals with glaucoma showing optic nerve head abnormalities such as rim thinning, notching, undermining, or retinal nerve fiber layer defects characteristic of glaucoma
- Two consecutive abnormal visual field tests with glaucoma hemifield test outside normal limits
You will not qualify if you...
- Media opacity such as lens, vitreous, or cornea
- Strabismus, nystagmus, or any condition preventing eye fixation
- Diabetes with evidence of retinopathy
- Previous intraocular surgery or eye trauma except laser procedures or uncomplicated cataract surgery more than 6 months before enrollment
- Neurological or non-glaucomatous causes of visual field damage
- Any intraocular non-glaucomatous eye disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
NYU Langone Health
New York, New York, United States, 10016
Actively Recruiting
Research Team
J
Jamika Singleton-Garvin
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here